Simon Nicholson

Organon Pharma (UK) Ltd. develops and manufactures pharmaceuticals. It offers osteoarthritis pain treatment Arcoxia, cardiovascular medication Cozaar, HIV drug Crixivan and asthma treatment Singulair. It operates a research center specializing in the development of central nervous system disorder such as Alzheimer's disease, depression, anxiety and migrane. The company was founded in 1953 and is headquartered in Hoddesdon, the United Kingdom.

Part of Merck & Co., Inc., S-P Ril Ltd. is an investment holding British company. The company is based in Hoddesdon, UK. S-P Ril was founded in 1961.

Founded in 1906, Dashtag is a part of Organon & Co. and operates an investment holding British company. The company is based in Hoddesdon, UK.

Schering-Plough Holdings Ltd. develops and manufactures pharmaceutical products. It offers sterilization tablets, cotton buds, and animal & veterinary health products. The company is headquartered in Welwyn Garden City, UK.

Part of Merck & Co., Inc., MSD R & D Innovation Centre Ltd. is a British pharmaceutical company founded in 1969. The company is based in Hoddesdon, UK. MSD is dedicated to following the science to address some of the most significant health challenges worldwide. The company may experience shortages of some products and may divest or discontinue others. MSD customer services are available during normal working hours, and the company authorizes the copying of materials published on its website for personal, non-commercial use only.

MSD Vaccines Ltd. manufactures and supplies vaccines. Its main way of achieving this goal is to develop and make available innovative vaccines against a wide spectrum of diseases. It also dedicated to increasing the understanding of the value of vaccines and vaccination by providing relevant and accurate information on their quality, safety and efficacy. The company was founded in 1975 and is headquartered in Maidenhead, the United Kingdom.

Part of Merck & Co., Inc., Merck Sharp & Dohme (UK) Ltd. is a British pharmaceutical company founded in 1928. The company is based in Hoddesdon, UK. MSD is investing $16 billion annually in capital projects over the next five years to meet the unprecedented demand for some vaccines. The company's scientists were among the first to develop medicines to treat hypertension, HIV, and Hepatitis C, among others, and they are committed to studying Alzheimer's disease. MSD's scientific discovery team and research collaborations across the life sciences ecosystem are well established and growing. The company works towards a shared purpose of driving medical advances against some of the world's greatest health threats.